Want to see SE:PROGEN full AI Analyst Report?
PROGEN Stock Chart & Stats
kr0.75
-kr0.32(-6.69%)
At close: 4:00 PM EST
kr0.75
-kr0.32(-6.69%)
Day’s Range― - ―
52-Week Rangekr0.08 - kr0.87
Previous CloseN/A
Volume7.01K
Average Volume (3M)7.92M
Market Cap
kr74.32M
Enterprise Valuekr25.06M
Total Cash (Recent Filing)kr392.00K
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta-0.24
Next Earnings
Feb 11, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.55
Shares Outstanding691,317,100
10 Day Avg. Volume3,572,344
30 Day Avg. Volume7,923,708
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.38
Price to Sales (P/S)17.06
P/FCF Ratio-0.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.08
Revenue Forecast (FY)kr1.23M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthThe recent increase in TTM revenue shows that Prostatype Genomics is generating greater commercial activity from its diagnostic offering. If sustained, this growth can improve operating leverage, support broader market penetration, and help establish a stronger base for future scale.
Precision Medicine FocusA focused precision-medicine model gives the company a clearly defined clinical purpose: using genomic and biomarker analysis to support prostate-cancer decisions. This specialized positioning can support durable relevance as healthcare providers seek more individualized risk assessment and treatment planning.
Manageable LeverageModest debt relative to equity provides some balance-sheet flexibility while the company develops its commercial business. Lower leverage can reduce financing pressure and interest-related constraints, leaving more capacity to direct future resources toward product development and market expansion.
Bears Say
Persistent UnprofitabilitySeverely negative gross, operating, and net margins show that current revenue does not cover the company’s cost base. Without a meaningful improvement in unit economics and operating efficiency, continued losses could limit reinvestment capacity and delay progress toward a scalable commercial model.
Sustained Cash BurnMaterially negative operating and free cash flow indicates that Prostatype Genomics continues to consume cash while funding its operations. Although the burn improved versus 2024, the multi-year negative pattern increases funding dependence and makes profitability improvement important for financial durability.
Scale And Execution RiskSmall, volatile revenue relative to the company’s asset base indicates that commercial scale has not yet been firmly established. The business must translate its diagnostic platform into substantially higher and more consistent sales, otherwise asset productivity and shareholder returns may remain weak.
PROGEN FAQ
What was Prostatype Genomics AB’s price range in the past 12 months?
Prostatype Genomics AB lowest stock price was kr0.08 and its highest was kr0.87 in the past 12 months.
What is Prostatype Genomics AB’s market cap?
Prostatype Genomics AB’s market cap is kr74.32M.
When is Prostatype Genomics AB’s upcoming earnings report date?
Prostatype Genomics AB’s upcoming earnings report date is Feb 11, 2027 which is in 103 days.
How were Prostatype Genomics AB’s earnings last quarter?
Prostatype Genomics AB released its earnings results on Aug 31, 2026. The company reported -kr0.111 earnings per share for the quarter.
Is Prostatype Genomics AB overvalued?
According to Wall Street analysts Prostatype Genomics AB’s price is currently Overvalued.
Does Prostatype Genomics AB pay dividends?
Prostatype Genomics AB does not currently pay dividends.
What is Prostatype Genomics AB’s EPS estimate?
Prostatype Genomics AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Prostatype Genomics AB have?
Prostatype Genomics AB has 691,317,100 shares outstanding.
What happened to Prostatype Genomics AB’s price movement after its last earnings report?
Prostatype Genomics AB reported an EPS of -kr0.111 in its last earnings report. Following the earnings report the stock price went down -6.711%.
Which hedge fund is a major shareholder of Prostatype Genomics AB?
Currently, no hedge funds are holding shares in SE:PROGEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Prostatype Genomics AB
Prostatype Genomics AB focuses on creating, marketing, and selling sophisticated prognostic gene tests. Their primary offering, the Prostatype Test System, combines genetic expression data with key clinical measurements such as PSA levels, Gleason Score, and Tumor Stage to determine a specific P-score. This advanced diagnostic tool is built upon a vast database of prostate cancer patients, providing crucial support for patients and medical practitioners when deciding on treatment strategies. Founded in 2007, the company is headquartered in Solna, Sweden.
Technical Analysis
Immunovia AB
―
Q-linea AB
―
Acarix AB
―
Biovica International AB Class B
―
Devyser Diagnostics AB
―